Eric Tsobanis

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

Nick Pavlakis, Katrin Marie Sjoquist, Andrew Martin et al. · Journal of Clinical Oncology · 2016 · 243 citations · Full text

Medicine, Oncology, Pharmacology +10

INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results.

Nick Pavlakis, Katrin Marie Sjoquist, Eric Tsobanis et al. · Journal of Clinical Oncology · 2015 · 19 citations

Medicine, Oncology, Pharmacology +11

INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.

Nick Pavlakis, Katrin Marie Sjoquist, Eric Tsobanis et al. · Journal of Clinical Oncology · 2015 · 13 citations

Medicine, Oncology, Pharmacology +16

Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).

Katrin Marie Sjoquist, Nick Pavlakis, Andrew Martin et al. · Journal of Clinical Oncology · 2017 · 10 citations

Medicine, Oncology, Pharmacology +14